Literature DB >> 10840164

Glutathione S-transferase-pi gene expression and platinum drug exposure in human lung cancer.

T Oguri1, Y Fujiwara, O Katoh, H Daga, N Ishikawa, K Fujitaka, M Yamasaki, M Yokozaki, T Isobe, S Ishioka, M Yamakido.   

Abstract

We examined the association between the gene expression levels of glutathione S-transferase-pi (GST-pi) and platinum drug exposure in human lung cancer. First we monitored GST-pi gene expression levels in two lung cancer cell lines and in peripheral mononuclear cells of ten previously untreated lung cancer patients after platinum drug exposure. Next we examined GST-pi gene expression levels in 40 lung cancer autopsy specimens. The GST-pi gene expression levels were assessed by the quantitative reverse transcription-polymerase chain reaction or Northern blot analysis. The GST-pi gene expression was not induced by platinum drugs either in vitro and in vivo within 24 h of exposure. In contrast, GST-pi gene expression levels in lung cancer tissues of patients who had been exposed to platinum drugs at least 1 month before death were significantly higher than that in those of patients who had not been exposed. These results suggest that GST-pi gene expression is associated with chronic exposure to platinum drugs in lung cancer and/or the stress response to xenobiotics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10840164     DOI: 10.1016/s0304-3835(00)00447-x

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  Genetic variability of glutathione S-transferases influences treatment outcome of breast cancer.

Authors:  Liang Zhou; Anzhong Huang; Dawei Zhang; Junliang Yao; Yong Zhang; Xuejiao Li
Journal:  Tumour Biol       Date:  2015-03-14

2.  Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.

Authors:  J-H Deng; J Deng; D-H Shi; X-N Ouyang; P-G Niu
Journal:  Clin Transl Oncol       Date:  2015-06-02       Impact factor: 3.405

3.  Association of GSTs gene polymorphisms with treatment outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.

Authors:  Gun Wu; Bin Jiang; Xiaoqin Liu; Yi Shen; Shujuan Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.

Authors:  Bateer Han; Zhanlin Guo; Ying Ma; Shirong Kang; Yufei Wang; Qiyou Wei; Xu Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

5.  MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.

Authors:  Ning Sun; Xinchen Sun; Baoan Chen; Hongyan Cheng; Jifeng Feng; Lu Cheng; Zuhong Lu
Journal:  Cancer Chemother Pharmacol       Date:  2009-07-01       Impact factor: 3.333

6.  Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.

Authors:  E Goekkurt; S Hoehn; C Wolschke; C Wittmer; C Stueber; D K Hossfeld; J Stoehlmacher
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

Review 7.  Gene therapy for cancer: present status and future perspective.

Authors:  Magid H Amer
Journal:  Mol Cell Ther       Date:  2014-09-10

8.  Influence of GSTP1 Polymorphism on the Clinical Outcomes of Patients With Advanced NSCLC Receiving First-Line Bevacizumab-Based Regimen: A Real-World Retrospective Study.

Authors:  Fei Han; Hanji Tian; Baoli Jin; Gang Chen
Journal:  Clin Med Insights Oncol       Date:  2021-12-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.